Thrombophilia Assessment Under DOAC: Effectiveness of Activated Charcoal

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Dec 12, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to assess thrombophilia, a condition that can lead to abnormal blood clotting, in patients who are taking direct oral anticoagulants (DOACs) like Apixaban, Rivaroxaban, or Dabigatran. These medications can affect certain blood tests that help doctors understand a person’s clotting ability. The researchers want to see if activated charcoal can help remove DOACs from the bloodstream, making it easier to perform these important tests.

To participate in this trial, you need to be an adult, at least 18 years old, and have a blood sample that has already been analyzed for your medical care. You also need to agree to allow the use of your medical information for research. If you join, you can expect to see how activated charcoal impacts the testing process. It’s important to note that participants must not have insufficient blood samples for the study. This trial is currently recruiting participants, and everyone is welcome to apply, regardless of gender.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Adult subject (≥ 18 years of age)
• • Blood sample already analyzed in a usual way in the laboratory as part of the care
• • Subject not objecting to the reuse of his or her medical data for scientific research purposes.
• Exclusion criteria:
• • - Insufficient sample